A breakthrough in the treatment of hepatitis B?
A new drug called Bepirovirsen holds the promise of new advances in the treatment of hepatitis B. The drug, a promising antisense oligonucleotide, is being developed by GSK (GlaxoSmithKline). Phase III data published in May 2026 showed significant functional cure rates (19% in the overall population, 26% in patients with lower viral activity), which could… Read More »